RegenKit®–Wound Gel supports point-of-care preparation of autologous PRP with a focus on controlled composition—delivering key biological components while reducing elements that may contribute to a disrupted wound environment.
99.7%
Red Blood Reduction
Single Blood Draw Volume
Point-Of-Care Preparation
PRP systems vary widely in platelet concentration, leukocyte content, red blood cell presence, and preparation methods. In chronic wounds—where inflammation is already dysregulated—composition matters.
RegenKit-Wound Gel is designed to deliver a controlled autologous PRP solution, supporting a standardized point-of-care preparation protocol while helping reduce unnecessary inflammatory burden in the wound environment.
In an already inflamed wound environment, introducing unnecessary inflammatory components may not support an optimal healing environment. The cellular profile of PRP matters.
Chronic wounds are often characterized by prolonged, dysregulated inflammation that disrupts normal healing progression. Understanding this environment is key to choosing the right intervention.
In healthy tissue repair, leukocyte activity and protease levels are regulated and temporary. In chronic wounds, these become persistently elevated — breaking down tissue and blocking progression toward closure.
Chronic wounds are often characterized by prolonged, dysregulated inflammation that disrupts normal healing progression. Understanding this environment is key to choosing the right intervention.
RegenKit–Wound Gel is supported by established reimbursement pathways that may help enable integration into clinical workflows across care settings.
Important considerations: coverage varies by payer and site of care, documentation and medical necessity requirements apply, and reimbursement policies may vary by MAC and geographic region.
Chronic diabetic wounds
Chronic non-diabetic wounds*